Format

Send to

Choose Destination
Phys Med Rehabil Clin N Am. 2018 Aug;29(3):473-481. doi: 10.1016/j.pmr.2018.03.003. Epub 2018 May 8.

Special Considerations and Assessment in Patients with Multiple Sclerosis.

Author information

1
Department of Physical Medicine and Rehabilitation, Lewis Katz School of Medicine, Temple University, 3401 North Broad Street, Philadelphia, PA 19140, USA. Electronic address: Ian.Maitin@tuhs.temple.edu.
2
Department of Physical Medicine and Rehabilitation, Lewis Katz School of Medicine, Temple University, 3401 North Broad Street, Philadelphia, PA 19140, USA.

Abstract

Multiple sclerosis is a progressive autoimmune neurologic disorder that may affect any region of the central nervous system. Spasticity in patients with multiple sclerosis can be debilitating and detrimental to the function and quality of life of patients. Treatment options include oral medications, chemodenervation, physical therapy, and modalities. Cannabinoids in the form of a delta-9-tetrahydrocannabinol/cannabidiol oro-mucosal spray has been shown to be effective in addressing spasticity in multiple sclerosis. Successful treatment of spasticity will be integrated, multimodal, and individualized.

KEYWORDS:

Botulinum toxin; Cannabinoids; Multiple sclerosis; Spasticity

PMID:
30626509
DOI:
10.1016/j.pmr.2018.03.003

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center